<DOC>
	<DOCNO>NCT01465347</DOCNO>
	<brief_summary>This open-label study evaluate safety efficacy TSC dose concomitantly standard care ( radiation therapy temozolomide ) newly diagnose glioblastoma adult . All patient receive TSC study . The objective study evaluate effect TSC survival tumor response patient GBM establish acceptable patient risk profile .</brief_summary>
	<brief_title>Safety Efficacy Study Trans Sodium Crocetinate ( TSC ) With Concomitant Radiation Therapy Temozolomide Newly Diagnosed Glioblastoma ( GBM )</brief_title>
	<detailed_description>The overall objective Phase 1/2 clinical study newly diagnose GBM patient evaluate safety tolerability , efficacy , PK profile , PFS/time disease progression , QoL , overall survival adult TSC add standard care regimen radiation therapy temozolomide . All patient receive TSC study . The primary objective Phase 1 portion study evaluate safety ( DLT rate ) define dose regimen TSC large Phase 2 study . The primary clinical endpoint overall survival 24 month patient follow 3 year .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Vitamin A</mesh_term>
	<criteria>Aged least 18 year age ; male female . A patient 70 year age older may consider enrollment review patient clinical laboratory data Protocol Medical Monitor . Histologically confirm diagnosis GBM . Contrast enhance disease MRI within 21 day prior Screening . Karnofsky score ( KPS ) ≥ 60 Screening . No prior RT , chemotherapy ( include Gliadel wafer ) , immunotherapy therapy biologic agent , hormonal therapy . Glucocorticoid therapy allow . Within 2 week Baseline visit , hematologic renal function specify : Absolute neutrophil count ≥ 1500/mm3 , platelet ≥ 100,000/mm3 , Hgb ≥ 9.0g/dL , creatinine ≤ 1.7mg/dl , total bilirubin ≤ 1.5mg/dL , blood urea nitrogen ( BUN ) within 2 time upper limit normal , transaminases ≤ 4 time upper limit institutional norm . Sexually active patient must use acceptable method contraception receive dos study medication . Females childbearing potential must negative serum urine pregnancy test Screening additional pregnancy test study . Pt . undergo MRI . Pregnant lactate . Serious concurrent infection medical illness would jeopardize ability patient receive study treatment reasonable safety . Pt . receive concurrent chemotherapeutics investigational agent within 30 day Baseline assessment , include gliadel wafer gliasite application .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Primary brain tumor</keyword>
	<keyword>Glioblastoma</keyword>
	<keyword>Glioma</keyword>
	<keyword>GBM</keyword>
	<keyword>Radiation therapy</keyword>
</DOC>